ERBB2 and breast cancer: The BCIRG-006 trial compared three chemotherapy regimens: doxorubicin, cyclophosphamide and docetaxel (AC-T), ACT plus trastuzumab (ACT-H), and docetaxel, carboplatin plus trastuzumab (TCH) for the treatment of HER-2-positive breast cancer [8].